SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Limerick BioPharma, Inc., a developer of innovative therapies that help cells pump out unwanted or toxic substances, will announce new results from human trials of its lead compound, LIM-0705, at the 23rd International Congress of the Transplantation Society in Vancouver, Canada, in an oral presentation on August 19, 2010. The results will be presented by Dr. Daniel C. Brennan, Professor of Medicine and Director of Transplant Nephrology at Washington University School of Medicine in St. Louis.
